[go: up one dir, main page]

IS7398A - Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun - Google Patents

Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun

Info

Publication number
IS7398A
IS7398A IS7398A IS7398A IS7398A IS 7398 A IS7398 A IS 7398A IS 7398 A IS7398 A IS 7398A IS 7398 A IS7398 A IS 7398A IS 7398 A IS7398 A IS 7398A
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
salt
dry granulation
granules
weight
Prior art date
Application number
IS7398A
Other languages
English (en)
Other versions
IS2393B (is
Inventor
Chrisopher Buxton Philip
Elizabeth Groves Sharon
Thomson Seona
Marinus Johannes Van Schie Dirk
Trevor Yeates Kenneth
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7398A publication Critical patent/IS7398A/is
Publication of IS2393B publication Critical patent/IS2393B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7398A 2002-02-14 2004-08-12 Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun IS2393B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition
PCT/GB2003/000217 WO2003068193A1 (en) 2002-02-14 2003-01-22 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation

Publications (2)

Publication Number Publication Date
IS7398A true IS7398A (is) 2004-08-12
IS2393B IS2393B (is) 2008-08-15

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7398A IS2393B (is) 2002-02-14 2004-08-12 Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun

Country Status (21)

Country Link
US (1) US20050075335A1 (is)
EP (1) EP1476136B1 (is)
JP (1) JP2005523276A (is)
KR (1) KR100967782B1 (is)
AT (1) ATE329581T1 (is)
AU (1) AU2003202058B2 (is)
BR (1) BR0307666A (is)
CA (1) CA2475659A1 (is)
CO (1) CO5611095A2 (is)
CY (1) CY1106148T1 (is)
DE (1) DE60306120T2 (is)
DK (1) DK1476136T3 (is)
ES (1) ES2263949T3 (is)
IS (1) IS2393B (is)
MX (1) MXPA04007857A (is)
NO (1) NO20043834L (is)
NZ (1) NZ534333A (is)
PL (1) PL206544B1 (is)
PT (1) PT1476136E (is)
RU (1) RU2329789C2 (is)
WO (1) WO2003068193A1 (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US20090148522A1 (en) * 2006-05-04 2009-06-11 James Kowalski Heated roller compaction process for making pharmaceutical compositions
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
DK2170292T3 (da) * 2007-06-22 2014-04-07 Bristol Myers Squibb Holdings Ireland Atazanavirholdige sammensætninger i tabletform
BRPI0815376A2 (pt) * 2007-07-31 2014-10-07 Cargill Inc Dextrose diretamente compresível
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) * 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
EP4138787A1 (en) * 2020-04-24 2023-03-01 Astrazeneca AB Pharmaceutical formulations
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
EP0376331A3 (en) * 1988-12-29 1991-03-13 Asahi Kogaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
ATE180785T1 (de) * 1992-03-12 1999-06-15 Smithkline Beecham Plc Kondensierte indol-derivate als 5-ht4-rezeptor- antagonisten
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
ES2151743T3 (es) * 1996-08-16 2001-01-01 Smithkline Beecham Plc Procedimiento para la preparacion de n-((1-n-butil-4-piperidinil)metil)-3,4-dihidro-2h-(1,3)-oxazino(3,2-a)indol-10-carboxamida y las sales y productos intermedios en el procedimiento.
CN100413539C (zh) * 2000-08-07 2008-08-27 葛兰素史密斯克莱实验室公司 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用
JP2004505920A (ja) * 2000-08-08 2004-02-26 スミスクライン ビーチャム パブリック リミテッド カンパニー 縮合インドール化合物を含む医薬組成物
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
KR100967782B1 (ko) 2010-07-05
IS2393B (is) 2008-08-15
ES2263949T3 (es) 2006-12-16
AU2003202058B2 (en) 2009-05-28
DE60306120D1 (de) 2006-07-27
ATE329581T1 (de) 2006-07-15
RU2004127450A (ru) 2005-04-10
PT1476136E (pt) 2006-10-31
CO5611095A2 (es) 2006-02-28
NO20043834L (no) 2004-10-26
PL371963A1 (en) 2005-07-11
HK1072359A1 (en) 2005-08-26
US20050075335A1 (en) 2005-04-07
KR20040097996A (ko) 2004-11-18
NZ534333A (en) 2006-05-26
MXPA04007857A (es) 2004-10-15
CY1106148T1 (el) 2011-06-08
CA2475659A1 (en) 2003-08-21
BR0307666A (pt) 2005-01-11
EP1476136B1 (en) 2006-06-14
PL206544B1 (pl) 2010-08-31
DE60306120T2 (de) 2006-11-09
JP2005523276A (ja) 2005-08-04
EP1476136A1 (en) 2004-11-17
RU2329789C2 (ru) 2008-07-27
WO2003068193A1 (en) 2003-08-21
DK1476136T3 (da) 2006-10-09
AU2003202058A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
IS2393B (is) Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
CA2470601A1 (en) Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
EP1893182B8 (en) Oral dosage forms comprising progesterone and method of making and using the same
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
JO2560B1 (en) Tablets decompose in the mouth and the process of their preparation
YU19301A (sh) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
SA94150373A (ar) صياغات جديدة واستخدام صياغة في علاج و/أوالوقاية من اضطرابات معينة
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
CA2469019A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
CA2353693A1 (en) Pharmaceutical composition containing citalopram
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
TW200509995A (en) Pharmaceutical composition as solid dosage form and method for manufacturing thereof
DK1501484T3 (da) Fremgangsmåde til fremstilling af tabletter ud fra farmaceutisk aktive stoffer som har uönskede tabletteringsegenskabler, med en granuleringsvæske der omfatter mikrokrystallinsk cellulose
RU2013127273A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, АДАПТИРОВАННАЯ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА НА ОСНОВЕ МОДИФИКАТОРА МОТОРИКИ КИШЕЧНИКА И ФЕРМЕНТА α-D-ГАЛАКТОЗИДАЗЫ
IL182549A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
TW200505504A (en) Saquinavir mesylate oral dosage form
CA2217238A1 (en) Cross-linked cellulose as a tablet excipient
WO2007010369B1 (en) Sustained release formulation of alprazolam
WO2005034919A3 (en) Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
WO2005034954A3 (en) Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
EA200600932A1 (ru) Таблетки циталопрама гидробромида
HRP20040165A2 (en) Citalopram for the treatment of elevated blood pressure
WO2005063202A3 (en) Method for preparing solid dosage form of desmopressin
TW200503728A (en) Suspension pharmaceutical composition containing budesonide and method for producing the same